DE69734359D1 - Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) - Google Patents
Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)Info
- Publication number
- DE69734359D1 DE69734359D1 DE69734359T DE69734359T DE69734359D1 DE 69734359 D1 DE69734359 D1 DE 69734359D1 DE 69734359 T DE69734359 T DE 69734359T DE 69734359 T DE69734359 T DE 69734359T DE 69734359 D1 DE69734359 D1 DE 69734359D1
- Authority
- DE
- Germany
- Prior art keywords
- vegf
- endothelial cell
- growth factor
- cell growth
- vascular endothelial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2375196P | 1996-08-23 | 1996-08-23 | |
US23751P | 1996-08-23 | ||
AUPO1825A AUPO182596A0 (en) | 1996-08-23 | 1996-08-23 | Growth factor |
AUPO182596 | 1996-08-23 | ||
AUPO3554A AUPO355496A0 (en) | 1996-11-11 | 1996-11-11 | Growth factor |
AUPO355496 | 1996-11-11 | ||
US3109796P | 1996-11-14 | 1996-11-14 | |
US31097P | 1996-11-14 | ||
AUPO495497 | 1997-02-05 | ||
AUPO4954A AUPO495497A0 (en) | 1997-02-05 | 1997-02-05 | Growth factors |
US3881497P | 1997-02-10 | 1997-02-10 | |
US38814P | 1997-02-10 | ||
AUPO743597 | 1997-06-19 | ||
AUPO7435A AUPO743597A0 (en) | 1997-06-19 | 1997-06-19 | Growth factor |
US5142697P | 1997-07-01 | 1997-07-01 | |
US51426P | 1997-07-01 | ||
PCT/US1997/014696 WO1998007832A1 (en) | 1996-08-23 | 1997-08-21 | Recombinant vascular endothelial cell growth factor d (vegf-d) |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69734359D1 true DE69734359D1 (de) | 2006-02-23 |
DE69734359T2 DE69734359T2 (de) | 2006-07-06 |
Family
ID=46149776
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69739469T Expired - Lifetime DE69739469D1 (de) | 1996-08-23 | 1997-08-21 | Rekombinanter vasculärer Endothelzellen Wachstumsfaktor D (VEGF-D) |
DE69734359T Expired - Lifetime DE69734359T2 (de) | 1996-08-23 | 1997-08-21 | Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69739469T Expired - Lifetime DE69739469D1 (de) | 1996-08-23 | 1997-08-21 | Rekombinanter vasculärer Endothelzellen Wachstumsfaktor D (VEGF-D) |
Country Status (11)
Country | Link |
---|---|
US (14) | US6235713B1 (de) |
EP (4) | EP2107109B1 (de) |
JP (3) | JP2001517075A (de) |
AT (2) | ATE306546T1 (de) |
AU (1) | AU729880C (de) |
CA (1) | CA2263890C (de) |
DE (2) | DE69739469D1 (de) |
DK (3) | DK0956339T3 (de) |
ES (3) | ES2327440T3 (de) |
HK (1) | HK1025789A1 (de) |
WO (1) | WO1998007832A1 (de) |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6824777B1 (en) | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
US6040157A (en) * | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
US6734285B2 (en) | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
US7153827B1 (en) | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
WO1995024473A1 (en) | 1994-03-08 | 1995-09-14 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
EP1382679A3 (de) | 1995-09-08 | 2004-11-10 | Genentech, Inc. | Antagonisten gegen Vaskuläres Endothelzellen Wachstumsfaktor-verwandtes Protein (VRP) |
ES2239338T5 (es) | 1995-09-29 | 2013-05-31 | Vegenics Pty Ltd | Genes regulados y sus usos |
US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
US6713061B1 (en) | 1996-03-12 | 2004-03-30 | Human Genome Sciences, Inc. | Death domain containing receptors |
US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
ES2242227T5 (es) * | 1996-07-15 | 2011-12-09 | Chugai Seiyaku Kabushiki Kaisha | Nuevo factor de tipo vegf. |
CA2263890C (en) | 1996-08-23 | 2013-05-14 | Ludwig Institute For Cancer Research | Recombinant vascular endothelial cell growth factor d (vegf-d) |
US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
AU765888B2 (en) * | 1997-12-24 | 2003-10-02 | Vegenics Limited | Expression vectors and cell lines expressing vascular endothelial growth factor D, and method of treating melanomas |
NZ505011A (en) * | 1997-12-24 | 2004-12-24 | Ludwig Inst Cancer Res | Expression vectors and cell lines expressing VEGF-D and method of treating melanomas |
ES2389387T3 (es) * | 1998-03-17 | 2012-10-25 | Genentech, Inc. | Polipéptidos homólogos de VEGF y de BMP1 |
EP0984063A3 (de) * | 1998-08-31 | 2000-08-16 | Eli Lilly And Company | Vegf-verwandtes gen und protein |
US20040053837A1 (en) * | 1998-09-30 | 2004-03-18 | Ludwig Institute For Cancer Research | Composition and method for modulating vasculogenesis or angiogenesis |
US20030211994A1 (en) * | 1998-09-30 | 2003-11-13 | Ludwig Institute For Cancer Research | Composition and method for modulating vasculogenesis or angiogenesis |
US20030082670A1 (en) * | 1998-09-30 | 2003-05-01 | Ulf Eriksson | Platelet-derived growth factor C, DNA coding therefor, and uses thereof |
CN100340291C (zh) | 1998-10-09 | 2007-10-03 | 路德维格癌症研究院 | F1t4(VEGFR-3)作为肿瘤显像和抗肿瘤治疗的靶 |
WO2000024412A2 (en) * | 1998-10-26 | 2000-05-04 | Ludwig Institute For Cancer Research | Use of vegf-c or vegf-d gene or protein to prevent restenosis |
US6958147B1 (en) | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
EP1568375A1 (de) * | 1998-10-26 | 2005-08-31 | Ludwig Institute For Cancer Research | Verwendung von VEGF-C oder VEGF-D Genen oder Proteinen zur Vorbeugung der Restenose |
EP1129110B1 (de) | 1998-11-10 | 2009-12-09 | Ludwig Institute For Cancer Research | Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen |
CA2354325C (en) * | 1998-12-07 | 2011-08-16 | Zymogenetics, Inc. | Growth factor homolog zvegf3 |
WO2000037025A2 (en) * | 1998-12-21 | 2000-06-29 | Ludwig Institute For Cancer Research | Antibodies to truncated vegf-d and uses thereof |
CA2356009C (en) * | 1998-12-22 | 2011-09-20 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-x |
US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
EP2357192A1 (de) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Menschliches alpha-Endokin und Verfahren zu seiner Verwendung |
CA2368670C (en) * | 1999-03-26 | 2012-06-05 | Chitra Suri | Modulation of vascular permeability by means of tie2 receptor activators |
WO2000058511A1 (en) | 1999-03-26 | 2000-10-05 | Ludwig Institute For Cancer Research | Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3) |
US6764820B2 (en) | 1999-03-26 | 2004-07-20 | Ludwig Institute For Cancer Research | Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3) |
US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
EP1206490A1 (de) * | 1999-08-16 | 2002-05-22 | Universita Degli Studi Di Siena | Vegf-d und dessen verwendung in der foerderung von angiogenese |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
US7045133B2 (en) | 2000-01-18 | 2006-05-16 | Ludwig Institute For Cancer Research | VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor |
US7727971B2 (en) | 2000-02-04 | 2010-06-01 | Life Sciences Research Partners Vzw | Use of placental growth factor for treating ischemic muscle disease |
US7105168B1 (en) | 2002-06-04 | 2006-09-12 | D. Collen Research Foundation Vzw | Method of improving ischemic muscle function by administering placental growth factor |
WO2001057181A2 (en) * | 2000-02-04 | 2001-08-09 | Carmeliet, Peter | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
US6930089B2 (en) | 2000-02-04 | 2005-08-16 | D. Collen Research Foundation Vzw | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke |
WO2001057008A1 (en) | 2000-02-07 | 2001-08-09 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
DE60131146T2 (de) | 2000-02-25 | 2008-03-06 | Ludwig Institute For Cancer Research | Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren |
DK1259248T3 (da) * | 2000-03-02 | 2005-04-11 | Ludwig Inst Cancer Res | Fremgangsmåde til behandling af cancere, der udtrykker vaskulær endotelvækstfaktor D |
US20020102260A1 (en) | 2000-03-02 | 2002-08-01 | Marc Achen | Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue |
AU2006201128B2 (en) * | 2000-03-02 | 2009-05-28 | Vegenics Limited | Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D |
ATE284701T1 (de) * | 2000-03-02 | 2005-01-15 | Ludwig Inst Cancer Res | Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren |
CA2405912A1 (en) | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2001082870A2 (en) * | 2000-05-03 | 2001-11-08 | Ludwig Institute For Cancer Research | A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof |
US7273751B2 (en) | 2000-08-04 | 2007-09-25 | Human Genome Science, Inc. | Vascular endothelial growth factor-2 |
JP2004527462A (ja) * | 2000-11-01 | 2004-09-09 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 血管新生活性のinvivo刺激 |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
AU2884102A (en) | 2000-12-07 | 2002-06-18 | Sangamo Biosciences Inc | Regulation of angiogenesis with zinc finger proteins |
US7611711B2 (en) | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
JP4669984B2 (ja) | 2001-01-19 | 2011-04-13 | ベジェニクス リミテッド | 腫瘍画像化のターゲットとしてのF1t4(VEGFR−3)および抗腫瘍療法 |
WO2002064097A2 (en) * | 2001-02-12 | 2002-08-22 | The Penn State Research Foundation | Vegf-d expression in brain cancer |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
US7402312B2 (en) | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
ATE470676T1 (de) | 2001-04-13 | 2010-06-15 | Human Genome Sciences Inc | Anti-vegf-2 antikörper |
WO2002098365A2 (en) * | 2001-06-07 | 2002-12-12 | Skinmedica, Inc. | Conditioned cell culture media and uses thereof |
CN1555488A (zh) * | 2001-07-12 | 2004-12-15 | 路德维格癌症研究院 | 淋巴管内皮细胞物质及方法 |
WO2003013570A1 (en) * | 2001-08-09 | 2003-02-20 | Cornell Research Foundation, Inc. | Platelet-derived growth factor protection of cardiac myocardium |
US20040214766A1 (en) * | 2001-10-01 | 2004-10-28 | Kari Alitalo | VEGF-C or VEGF-D materials and methods for treatment of neuropathologies |
US20030113324A1 (en) * | 2001-10-01 | 2003-06-19 | Kari Alitalo | Neuropilin/VEGF-C/VEGFR-3 materials and methods |
AU2002363369B2 (en) | 2001-10-15 | 2008-08-21 | Janssen Pharmaceutica N.V. | Substituted 4-phenyl-4-(1H-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
CN1653080A (zh) * | 2002-03-07 | 2005-08-10 | 路德维格癌症研究院 | 淋巴管和血管的内皮细胞基因 |
US7241446B2 (en) * | 2002-04-01 | 2007-07-10 | Trustees Of Dartmouth College | Methods for modulating angiogenesis via VEGF |
US7510714B2 (en) * | 2002-04-01 | 2009-03-31 | Trustees Of Dartmouth College | Methods for modulating angiogenesis |
WO2003093419A2 (en) * | 2002-05-03 | 2003-11-13 | Ludwig Institute For Cancer Research | Preventing secondary lymphedema with vegf-d dna |
NZ537579A (en) | 2002-06-10 | 2006-10-27 | Vaccinex Inc | C35 peptide epitopes and their analogs |
CA2493572A1 (en) | 2002-07-23 | 2004-01-29 | Ludwig Institute For Cancer Research | Methods and compositions for activating or inhibiting vegf-d and vegf-c |
US20040120950A1 (en) * | 2002-12-20 | 2004-06-24 | Kari Alitalo | Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis |
JP2006517586A (ja) * | 2003-02-04 | 2006-07-27 | ラドウィグ インスティテュート フォー キャンサー リサーチ | 幹細胞のvegf−b及びpdgf調節 |
US20050043235A1 (en) * | 2003-06-12 | 2005-02-24 | Kari Alitalo | Use of VEGF-C or VEGF-D in reconstructive surgery |
WO2005016963A2 (en) * | 2003-06-12 | 2005-02-24 | Ludwig Institute For Cancer Research | Heparin binding veger-3 ligands |
US20070110744A1 (en) * | 2003-09-08 | 2007-05-17 | Kari Alitalo | Lymphatic and blood endothelial cell genes |
US7284505B1 (en) | 2003-11-03 | 2007-10-23 | Paxton Stephen E | Skijor system |
US7780973B2 (en) * | 2003-12-15 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Method and device for minimally invasive implantation of biomaterial |
AU2004309090A1 (en) * | 2003-12-29 | 2005-07-14 | Aventis Pharma Sa | Treatment of coronary or peripheral ischemia |
US20050142161A1 (en) * | 2003-12-30 | 2005-06-30 | Freeman Lynetta J. | Collagen matrix for soft tissue augmentation |
WO2005087812A1 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
US20060024302A1 (en) * | 2004-03-05 | 2006-02-02 | Ludwig Institute For Cancer Research | Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same |
WO2005093098A1 (en) * | 2004-03-12 | 2005-10-06 | Ludwig Institute For Cancer Research | Differential drug sensitivity |
US7595149B1 (en) | 2004-11-08 | 2009-09-29 | University Of Kentucky Research Foundation | Methods for cancer detection |
WO2006094106A2 (en) | 2005-02-28 | 2006-09-08 | Sangamo Biosciences, Inc. | Anti-angiogenic methods and compositions |
ES2363758T3 (es) | 2005-08-15 | 2011-08-16 | Vegenics Pty Ltd | Vegf y pdgf modificados con propiedades angiogénicas mejoradas. |
TW200732347A (en) * | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
TWI428143B (zh) | 2006-01-18 | 2014-03-01 | Gen Hospital Corp | 增加淋巴功能之方法 |
ES2429225T3 (es) | 2006-05-17 | 2013-11-13 | The Ludwig Institute For Cancer Research | Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico |
WO2008093246A2 (en) | 2007-02-02 | 2008-08-07 | Vegenics Limited | Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis |
US20080267924A1 (en) * | 2007-02-07 | 2008-10-30 | Vegenics Limited | Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery |
US7811776B2 (en) | 2007-12-05 | 2010-10-12 | University Of Cincinnati | Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis (LAM) disease |
CA2710680C (en) | 2007-12-26 | 2018-10-16 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
WO2009143584A1 (en) * | 2008-05-30 | 2009-12-03 | Vegenics Limited | Treatment of pulmonary edema |
US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
US8255807B2 (en) * | 2008-12-23 | 2012-08-28 | Ganz | Item customization and website customization |
US20120093811A1 (en) * | 2009-04-03 | 2012-04-19 | Simmonds Jason W | Anti-vegf-d antibodies |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
EP2538965B1 (de) * | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutische zusammensetzungen zur behandlung des syndroms des trockenen auges |
WO2011154308A1 (en) | 2010-06-08 | 2011-12-15 | Proyecto De Biomedicina Cima, S.L. | New compositions and cell therapy methods for the treatment of cirrhosis |
WO2012088563A1 (en) * | 2010-11-24 | 2012-07-05 | Vegenics Pty Limited | Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof |
US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
US9415090B2 (en) * | 2011-06-01 | 2016-08-16 | Universität Heidelberg | VEGF-D/VEGFR2/3-mediated regulation of dendrites |
US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
US10457713B2 (en) | 2012-07-30 | 2019-10-29 | Trophogen, Inc. | Glycoprotein hormone long-acting superagonists |
PT3572515T (pt) | 2012-07-30 | 2021-10-22 | Trophogen Inc | Superagonistas de ação prolongada de hormonas glicoproteicas |
ES2682345T3 (es) | 2012-09-27 | 2018-09-20 | Biocare Medical, Llc | Sistemas y procedimientos de anticuerpos antiuroplaquina II |
WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
US9745558B2 (en) | 2013-02-18 | 2017-08-29 | Vegenics Pty Limited | VEGFR-3 ligand binding molecules and uses thereof |
DK2962113T3 (da) | 2013-02-28 | 2019-07-01 | Biocare Medical Llc | Systemer og fremgangsmåder med anti-p40-antistoffer |
DK3052522T3 (da) | 2013-10-03 | 2020-02-24 | Biocare Medical Llc | Anti-sox 10 antistofsystemer og -fremgangsmåder |
BR112016009962A2 (pt) | 2013-11-05 | 2017-12-05 | Trophogen Inc | superagonistas de ação prolongada de hormônio glicoproteico |
EP3924367A4 (de) * | 2019-04-04 | 2022-10-12 | Sree Chitra Tirunal Institute for Medical Sciences and Technology | Gefässendothelwachstumsfaktor (vegf) zur besseren wundheilung durch erhöhte angiogenese |
CN116981778A (zh) * | 2021-03-10 | 2023-10-31 | 住友制药株式会社 | 半胱氨酸结蛋白的制造方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968778A (en) * | 1989-01-12 | 1999-10-19 | Jurgen Hoppe | PDGF-AB, preparation process and pharmaceuticals containing them |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US6207454B1 (en) * | 1989-10-16 | 2001-03-27 | Amgen Inc. | Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide |
US5476839A (en) * | 1990-07-10 | 1995-12-19 | Incyte Pharmaceuticals, Inc. | Basophil granule proteins |
JP3024311B2 (ja) | 1991-10-03 | 2000-03-21 | 味の素株式会社 | Il−2受容体重鎖に結合するポリペプチド |
JPH05271294A (ja) | 1992-01-24 | 1993-10-19 | Japan Found Cancer Res | ヒトプロヒビチンおよびそれをコードするdna |
PL307258A1 (en) | 1992-07-27 | 1995-05-15 | Pfizer | Peptides capable to block calcium canals with agelenopsis aperta |
US5510239A (en) * | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
WO1995024473A1 (en) * | 1994-03-08 | 1995-09-14 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
DE4423098A1 (de) | 1994-07-01 | 1996-01-04 | Hoechst Ag | Verwendung von Pyrimidingruppen enthaltenden konjugierten Verbindungen als Elektrolumineszenzmaterialien |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
US6221839B1 (en) * | 1994-11-14 | 2001-04-24 | Helsinki University Licensing Ltd. Oy | FIt4 ligand and methods of use |
JPH08185216A (ja) | 1994-12-28 | 1996-07-16 | Meidensha Corp | 工具姿勢パラメータ設定方法及びロボット制御装置 |
US5928939A (en) | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
CN1194090C (zh) | 1995-03-02 | 2005-03-23 | 阿穆拉德业务有限公司 | 一种新的生长因子和编码这种生长因子的基因序列 |
WO1996039421A1 (en) | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 3 |
EP1382679A3 (de) * | 1995-09-08 | 2004-11-10 | Genentech, Inc. | Antagonisten gegen Vaskuläres Endothelzellen Wachstumsfaktor-verwandtes Protein (VRP) |
ES2239338T5 (es) * | 1995-09-29 | 2013-05-31 | Vegenics Pty Ltd | Genes regulados y sus usos |
JP3843488B2 (ja) | 1996-06-06 | 2006-11-08 | アイシン・エィ・ダブリュ株式会社 | 自動変速機の制御装置 |
ES2242227T5 (es) | 1996-07-15 | 2011-12-09 | Chugai Seiyaku Kabushiki Kaisha | Nuevo factor de tipo vegf. |
CA2263890C (en) * | 1996-08-23 | 2013-05-14 | Ludwig Institute For Cancer Research | Recombinant vascular endothelial cell growth factor d (vegf-d) |
AU5439998A (en) * | 1996-12-06 | 1998-06-29 | Zymogenetics Inc. | Vascular endothelial growth factor |
US20020165174A1 (en) * | 1997-01-31 | 2002-11-07 | Gill Parkash S. | Methods and compositions for antisense VEGF oligonucleotides |
NZ505011A (en) | 1997-12-24 | 2004-12-24 | Ludwig Inst Cancer Res | Expression vectors and cell lines expressing VEGF-D and method of treating melanomas |
DE19817835C2 (de) | 1998-04-22 | 2000-05-18 | Billhofer Maschf Gmbh | Sichtkaschiervorrichtung |
DE19823359C1 (de) | 1998-05-15 | 1999-10-07 | Francotyp Postalia Gmbh | Vorrichtung zum Bedrucken von Postgut |
WO2000037025A2 (en) | 1998-12-21 | 2000-06-29 | Ludwig Institute For Cancer Research | Antibodies to truncated vegf-d and uses thereof |
EP1206490A1 (de) * | 1999-08-16 | 2002-05-22 | Universita Degli Studi Di Siena | Vegf-d und dessen verwendung in der foerderung von angiogenese |
US20050043235A1 (en) | 2003-06-12 | 2005-02-24 | Kari Alitalo | Use of VEGF-C or VEGF-D in reconstructive surgery |
US20070212390A1 (en) | 2005-09-22 | 2007-09-13 | Ludwig Institute For Cancer Research | Protease-resistant forms of VEGF-D, method of making and method of use |
FR2987282B1 (fr) | 2012-02-24 | 2017-12-29 | Fonds De L'espci Georges Charpak | Microcanal avec dispositif d'ouverture et/ou fermeture et/ou pompage |
US9405291B2 (en) | 2012-07-31 | 2016-08-02 | Fisher-Rosemount Systems, Inc. | Systems and methods to monitor an asset in an operating process unit |
US9516755B2 (en) | 2012-12-28 | 2016-12-06 | Intel Corporation | Multi-channel memory module |
US9426605B2 (en) | 2013-10-10 | 2016-08-23 | Yahoo! Inc. | Cross device information exchange using gestures and locations |
-
1997
- 1997-08-21 CA CA2263890A patent/CA2263890C/en not_active Expired - Fee Related
- 1997-08-21 AU AU40796/97A patent/AU729880C/en not_active Ceased
- 1997-08-21 AT AT97938486T patent/ATE306546T1/de not_active IP Right Cessation
- 1997-08-21 EP EP09162873A patent/EP2107109B1/de not_active Expired - Lifetime
- 1997-08-21 DK DK97938486T patent/DK0956339T3/da active
- 1997-08-21 AT AT06121918T patent/ATE434034T1/de not_active IP Right Cessation
- 1997-08-21 WO PCT/US1997/014696 patent/WO1998007832A1/en active IP Right Grant
- 1997-08-21 DK DK09162873.5T patent/DK2107109T3/da active
- 1997-08-21 JP JP51095398A patent/JP2001517075A/ja active Pending
- 1997-08-21 DK DK06121918T patent/DK1749836T3/da active
- 1997-08-21 US US08/915,795 patent/US6235713B1/en not_active Expired - Fee Related
- 1997-08-21 EP EP02018842A patent/EP1283268A3/de not_active Withdrawn
- 1997-08-21 EP EP06121918A patent/EP1749836B1/de not_active Expired - Lifetime
- 1997-08-21 DE DE69739469T patent/DE69739469D1/de not_active Expired - Lifetime
- 1997-08-21 ES ES06121918T patent/ES2327440T3/es not_active Expired - Lifetime
- 1997-08-21 ES ES97938486T patent/ES2251740T3/es not_active Expired - Lifetime
- 1997-08-21 ES ES09162873T patent/ES2390107T3/es not_active Expired - Lifetime
- 1997-08-21 DE DE69734359T patent/DE69734359T2/de not_active Expired - Lifetime
- 1997-08-21 EP EP97938486A patent/EP0956339B1/de not_active Revoked
-
1999
- 1999-04-22 US US09/296,275 patent/US6689580B1/en not_active Expired - Fee Related
-
2000
- 2000-05-17 HK HK00102970A patent/HK1025789A1/xx not_active IP Right Cessation
-
2002
- 2002-06-05 US US10/161,694 patent/US7410639B2/en not_active Expired - Fee Related
- 2002-10-22 US US10/274,953 patent/US7122654B2/en not_active Expired - Fee Related
-
2003
- 2003-11-12 US US10/705,476 patent/US20040175730A1/en not_active Abandoned
-
2005
- 2005-12-16 US US11/304,585 patent/US20060177428A1/en not_active Abandoned
-
2007
- 2007-01-24 JP JP2007013569A patent/JP2007167072A/ja active Pending
- 2007-03-28 US US11/692,753 patent/US20080145366A1/en not_active Abandoned
- 2007-06-29 US US11/772,089 patent/US7662932B2/en not_active Expired - Fee Related
- 2007-08-23 US US11/843,867 patent/US7871798B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/929,537 patent/US7785803B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/929,120 patent/US7928061B2/en not_active Expired - Fee Related
-
2009
- 2009-07-10 JP JP2009164162A patent/JP2009291198A/ja active Pending
-
2011
- 2011-03-16 US US13/049,308 patent/US8227410B2/en not_active Expired - Fee Related
-
2012
- 2012-05-17 US US13/474,273 patent/US8445234B2/en not_active Expired - Fee Related
-
2013
- 2013-04-19 US US13/866,266 patent/US8759286B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69734359D1 (de) | Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d) | |
NO973933L (no) | Vaskulær endotelvekstfaktor B | |
DE69941791D1 (de) | Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen | |
ATE391778T1 (de) | Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen | |
DE3851153D1 (de) | Genetische modifizierung von endothelialen zellen. | |
PT93910A (pt) | Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula | |
DE69033710D1 (de) | Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein | |
DE69434538D1 (de) | Vaskularer endothelialer wachstumsfaktor 2 | |
DE3786321T2 (de) | Expression von Protein-C. | |
DE69434332D1 (de) | Thrombin mutanten | |
IL70776A (en) | Recombinant dna molecule encoding at least one polypeptide displaying the immunogenicity of at least one merozoite antigen or asexual blood stage antigen of p.falciparum,vectors comprising the dna molecule,host cells transformed thereby,immunogenic polypeptides produced by host cells and compositions containing the polypeptides | |
DE3751269T2 (de) | Expression des biologisch aktiven Faktors XIII. | |
WO2002050111A3 (en) | Isolated laminin 10 | |
WO2001053324A3 (en) | Novel haptotactic peptides | |
WO2001040257A3 (en) | Modified il-12 subunits and nucleic acids encoding them | |
WO1990003394A3 (fr) | Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines | |
WO2002059618A3 (en) | Growth factor polypeptides and nucleic acids encoding same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: LUDWIG INSTITUTE FOR CANCER RESEARCH, NEW YORK, N. Owner name: LICENTIA OY, HELSINKI, FI |
|
8363 | Opposition against the patent | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: VEGENICS LTD., TOORAK, VICTORIA, AU |